Floatz logo

Oncos-102

Advanced or Unresectable Melanoma Progressing After PD1 Blockade

Targovax Oygene_therapyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

449 Active assets in the Advanced or Unresectable Melanoma Progressing After PD1 Blockade cohort.

Asset / SponsorPhaseRating
Gm-Csf
Ultimovacs ASA
Phase 4BBB
Sargramostim
Mayo Clinic
Phase 3BBB
Cediranib
M.D. Anderson Cancer Center
Phase 3BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Cyclophosphamide
Primmune Therapeutics, Inc.
Phase 4BB

View all 50 →

Same molecule, other indications

Oncos-102 is also rated in:

appendix cancerDormant
CCC
Indicative ·
52 / 100
View asset →
cancerDormant
CC
Indicative ·
47 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →